BioVie (NASDAQ:BIVI) & Traws Pharma (NASDAQ:TRAW) Head-To-Head Analysis

BioVie (NASDAQ:BIVI) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability.

Institutional & Insider Ownership

4.6% of BioVie shares are held by institutional investors. Comparatively, 8.0% of Traws Pharma shares are held by institutional investors. 0.9% of BioVie shares are held by company insiders. Comparatively, 14.0% of Traws Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

BioVie has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for BioVie and Traws Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1	0	0	0	1.00
Traws Pharma	1	1	1	1	2.50

Traws Pharma has a consensus price target of $8.00, indicating a potential upside of 325.53%. Given Traws Pharma’s stronger consensus rating and higher possible upside, analysts plainly believe Traws Pharma is more favorable than BioVie.

Profitability

This table compares BioVie and Traws Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-101.15%	-90.18%
Traws Pharma	N/A	112.18%	35.31%

Valuation & Earnings

This table compares BioVie and Traws Pharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$17.54 million	($3.25)	-0.40
Traws Pharma	$2.79 million	6.85	$9.17 million	$0.93	2.02

Traws Pharma has higher revenue and earnings than BioVie. BioVie is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Traws Pharma beats BioVie on 13 of the 13 factors compared between the two stocks.

About BioVie

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

About Traws Pharma

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.